The TTD Group collects data from more than 5,000 cases of pancreatic cancer in Spain

The RETUD register of the TTD Group compiles data on more than 5,000 patients with pancreatic cancer and alerts to the challenge of equitable access to new therapies.

Add DEMÓCRATA to Google

Ask FREN

Published

2 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 20 de noviembre de 2026 · 19 institutos

  • PP31,0 %
  • PSOE27,9 %
  • Vox19,0 %
  • Frente Amplio6,2 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

The Digestive Tumors Treatment Group (TTD) has managed to compile in its RETUD registry clinical information from more than 5,000 people with pancreatic cancer, from 74 hospitals across 16 autonomous communities. This is one of the broadest databases in Spain for analyzing how this tumor is managed in everyday care practice.

Experts from the TTD highlight the value of these observational registries as a complement to the data provided by clinical trials—something that is especially relevant in pancreatic cancer, which specialists recall as one of the tumors with the worst survival rates.

Compared with the controlled conditions and strict inclusion criteria of trials, real-world registries like RETUD make it possible to track the evolution of patients of different ages, clinical profiles, and tumor characteristics treated in the day-to-day routine of oncology services.

Along these lines, the president of the TTD Group and Head of the Medical Oncology Service at Hospital Universitario Marqués de Valdecilla, Fernando Rivera, notes that RETUD helps answer questions that trials do not reach, by reflecting patients’ reality more faithfully and facilitating the identification of areas for improvement in care.

RETUD has already served as the basis for work that provides a picture of pancreatic cancer as oncologists see it in the consulting room. "Patients in clinical practice are more heterogeneous than those usually included in a trial, and knowing their results helps us understand where we are and what we need to improve," explained Teresa Macarulla, co-coordinator of the working group on pancreatic and biliary tract tumors of the TTD and Head of the Medical Oncology Service at Hospital Clínic de Barcelona.

This type of information is especially useful at a time of relevant advances in the approach to pancreatic cancer, driven by targeted therapies against alterations in the RAS gene. Despite this, specialists insist that it is essential to continue investigating to clarify why certain tumors respond to these treatments and others do not.

In this context, RETUD can play a key role by integrating clinical and molecular data on different biomarkers and alterations involved in pancreatic cancer, beyond RAS/KRAS, and also having a collection of biological samples associated with the clinical information. As new therapies are incorporated into routine practice, this repository will make it possible to evaluate their effect outside the trial setting and to propose new lines of translational research.

Challenge of equity in access

However, oncologists warn that the emergence of new therapeutic options comes with a challenge in terms of equitable access, both to these treatments and to clinical trials, since not all hospital centers can offer them.

For the co-coordinator of the working group on tumors of the pancreas and biliary pathways of the TTD and medical oncologist at the Hospital Universitario 12 de Octubre de Madrid, Jorge Adeva, "coordination between hospitals will be fundamental" in order to refer patients to the centers where they can receive the treatment or participate in the most appropriate trial, preventing the place of residence from becoming a barrier.

The Asociación Cáncer de Páncreas (ACANPAN) agrees in pointing out the access challenge and the need to set up agile, coordinated referral pathways between hospitals. "It is essential to speed up the evaluation and financing processes so that the innovative treatments that have demonstrated clinical benefit can be available in Spain at the moment they are approved in Europe, and to guarantee equitable access throughout the national territory, regardless of where each patient lives," they said.